Actavis to Quit China as Trouble Seen for Little Profit

Actavis Plc, the second-biggest generic drugmaker by market capitalization, said it will end its presence in China because of the difficult business climate.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.